Last reviewed · How we verify
Shanghai Haiyan Pharmaceutical Technology Co., Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
3 Phase 3
1 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Active Comparator: Morphine | Active Comparator: Morphine | phase 3 | Opioid analgesic | Mu-opioid receptor (μ-OR) | Pain Management | |
| Experimental: YZJ-4729 | Experimental: YZJ-4729 | phase 3 | ||||
| YZJ-1139 | YZJ-1139 | phase 3 | SGLT2 inhibitor | SGLT2 | Diabetes |
Therapeutic area mix
- Diabetes · 1
- Pain Management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Teva Branded Pharmaceutical Products R&D, Inc. · 2 shared drug classes
- Ain Shams University · 2 shared drug classes
- GlaxoSmithKline · 2 shared drug classes
- Kyowa Kirin Co., Ltd. · 2 shared drug classes
- University of British Columbia · 2 shared drug classes
- University of Minnesota · 2 shared drug classes
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
- AceLink Therapeutics, Inc. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Shanghai Haiyan Pharmaceutical Technology Co., Ltd.:
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd. pipeline updates — RSS
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd. pipeline updates — Atom
- Shanghai Haiyan Pharmaceutical Technology Co., Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Shanghai Haiyan Pharmaceutical Technology Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-haiyan-pharmaceutical-technology-co-ltd. Accessed 2026-05-17.